Effect of low-calcium hemodialysate on bone metabolism.
In the present study, we investigated the kinetics of bone metabolism by determining serum bone metabolic markers and quantifying bone mineral density by dual-energy X-ray absorptiometry to clarify the effect of long-term use of low-calcium hemodialysate on bone metabolism. After changing the calcium concentration in the dialysate from 3.0 mEq/l to 2.5 mEq/l, serum intact parathyroid hormone level, serum highly sensitive parathyroid hormone level, and serum bone metabolic markers were determined in ten patients with chronic nondiabetic renal insufficiency during 1 year. The doses of an oral phosphate binder and activated vitamin D were carefully regulated to control serum ionized calcium levels and serum inorganic phosphorus levels. Bone mineral density was determined at the distal 1/3 and 1/6 of the radius on the nonshunt side. As a result, the required amount of oral phosphate binder was increased; however, there was no need to significantly increase the amount of activated vitamin D. Intact parathyroid hormone showed no significant variation, but the highly sensitive parathyroid hormone was significantly increased. There were no significant changes in any bone metabolic markers or in bone mineral density. From these study results, it was found that it was difficult to increase the dose of activated vitamin D even if low-calcium hemodialysate was used, and that during use of the low-calcium hemodialysate the serum level of parathyroid hormone tended to increase but led to neither acceleration of bone turnover nor a decrease in bone mineral density.
Saisu
T
T
Department of Orthopaedic Surgery, School of Medicine, Chiba University, Japan.
Wakabayashi
Y
Y
Yamada
K
K
Shigematsu
T
T
Goto
S
S
Nishimura
M
M
Miura
Y
Y
Nakano
H
H
Moriya
H
H
D015502:Absorptiometry, Photon; D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D015415:Biomarkers; D015519:Bone Density; D001842:Bone and Bones / Q000378:metabolism*; D002118:Calcium / Q000008:administration & dosage / Q000494:pharmacology*; D002119:Calcium Carbonate / Q000008:administration & dosage / Q000494:pharmacology; D002762:Cholecalciferol / Q000097:blood; D005260:Female; D015312:Hemodialysis Solutions / Q000494:pharmacology*; D006801:Humans; D006887:Hydroxycholecalciferols / Q000008:administration & dosage / Q000494:pharmacology; D007527:Isoenzymes / Q000097:blood; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D010758:Phosphorus / Q000097:blood; D011347:Procollagen / Q000097:blood; D006435:Renal Dialysis
D015415:Biomarkers; D015312:Hemodialysis Solutions; D006887:Hydroxycholecalciferols; D007527:Isoenzymes; D010281:Parathyroid Hormone; D010446:Peptide Fragments; D011347:Procollagen; C042813:procollagen type I carboxy terminal peptide; D002762:Cholecalciferol; D010758:Phosphorus; D000469:Alkaline Phosphatase; D002119:Calcium Carbonate; D002118:Calcium; C008088:alfacalcidol